Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL1889719 | 0.98 | PABPC1 (0.42) | ALDH1A1KDM4EPABPC1HPGDMAPT | |
| Bromide SCHEMBL1889463 | 0.98 | PABPC1 (0.40) | ALDH1A1KDM4EPABPC1HPGD | |
| SCHEMBL15993624 | 0.94 | MEN1 (0.46) | KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL12639175 | 0.94 | MEN1 (0.46) | KDM4EMAPTHTTSMN1; SMN2 | |
| SCHEMBL15993308 | 0.94 | MEN1 (0.46) | KDM4EMAPTHTTSMN1; SMN2 | |
| Iodide SCHEMBL1883901 | 0.92 | HTT (0.47) | KDM4EMAPTHTTSMN1; SMN2 | |
| Bromide SCHEMBL15992884 | 0.92 | — | — | |
| Bromide SCHEMBL1877140 | 0.92 | — | — | |
| SCHEMBL12639157 | 0.86 | KDM4E (0.49) | ALDH1A1KDM4EPABPC1HPGDMAPT | |
| SCHEMBL12639143 | 0.86 | KDM4E (0.49) | ALDH1A1KDM4EPABPC1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663386-B2 | Extraction of noble metal (ions) by means of ionic liquids | TECHNISCHE UNIVERSITAT DRESDEN (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-2739572-B1 | EXTRACTION OF METAL (IONS) BY MEANS OF IONIC LIQUIDS | UNIV DRESDEN TECH (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-2254871-B1 | SALTS COMPRISING ARYL-ALKYL-SUBSTITUTED IMIDAZOLIUM AND TRIAZOLIUM CATIONS AS IONIC FLUIDS | UNIV DRESDEN TECH (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9260397-B2 | Salts comprising aryl-alkyl-substituted imidazolium and triazolium cations and the use thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2016-02-16 | — | — | US | disclosed |
| US-20140246370-A1 | EXTRACTION OF NOBLE METAL (IONS) BY MEANS OF IONIC LIQUIDS | HELMHOLTZ-ZENTRUM DRESDEN - ROSSENDORF E.V. (DE) | 2014-09-04 | — | — | US | disclosed |
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | TECHNISCHE UNIVERSITAET DRESDEN (DE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105761-A1 | Salts Comprising Aryl-Alkyl-Substituted Imidazolium and Triazolium Cations and the Use Thereof | RDX, HAX1, CHRM2 | ALDH1A1 2684/4885KDM4E 4534/4885PABPC1 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.